[go: up one dir, main page]

MX2017009292A - Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3. - Google Patents

Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.

Info

Publication number
MX2017009292A
MX2017009292A MX2017009292A MX2017009292A MX2017009292A MX 2017009292 A MX2017009292 A MX 2017009292A MX 2017009292 A MX2017009292 A MX 2017009292A MX 2017009292 A MX2017009292 A MX 2017009292A MX 2017009292 A MX2017009292 A MX 2017009292A
Authority
MX
Mexico
Prior art keywords
methyl
receptor modulators
piperazine derivatives
cxcr3 receptor
cxcr3
Prior art date
Application number
MX2017009292A
Other languages
English (en)
Inventor
Caroff Eva
Meyer Emmanuel
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MX2017009292A publication Critical patent/MX2017009292A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)

Abstract

La invención se refiere a compuestos de Fórmula (I) en donde R1 y R2 son como se describe en la descripción; a sales farmacéuticamente aceptables de los mismos y al uso de dichos compuestos como medicamentos, especialmente como moduladores del receptor CXCR3.
MX2017009292A 2015-01-15 2016-01-14 Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3. MX2017009292A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2015050691 2015-01-15
PCT/EP2016/050659 WO2016113346A1 (en) 2015-01-15 2016-01-14 (r)-2-methyl-piperazine derivatives as cxcr3 receptor modulators

Publications (1)

Publication Number Publication Date
MX2017009292A true MX2017009292A (es) 2018-02-09

Family

ID=55129889

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009292A MX2017009292A (es) 2015-01-15 2016-01-14 Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.

Country Status (16)

Country Link
US (1) US10047080B2 (es)
EP (1) EP3256469B1 (es)
JP (1) JP6595003B2 (es)
KR (1) KR102568469B1 (es)
CN (1) CN107207491B (es)
AR (1) AR103399A1 (es)
AU (1) AU2016207990B2 (es)
BR (1) BR112017015116A2 (es)
CA (1) CA2972954C (es)
ES (1) ES2712727T3 (es)
MX (1) MX2017009292A (es)
PL (1) PL3256469T3 (es)
RU (1) RU2706232C2 (es)
TR (1) TR201901977T4 (es)
TW (1) TWI698434B (es)
WO (1) WO2016113346A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX363432B (es) 2013-07-22 2019-03-22 Idorsia Pharmaceuticals Ltd Derivados 1-(piperazin-1-il)-2-([1,2,4]triazol-1-il)-etanona.
AR099789A1 (es) 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
NZ734542A (en) 2015-01-15 2023-02-24 Idorsia Pharmaceuticals Ltd Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
WO2018011265A1 (en) * 2016-07-13 2018-01-18 Idorsia Pharmaceuticals Ltd Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
CN110183388A (zh) * 2019-06-06 2019-08-30 常州合全药业有限公司 一种2-（1h-1,2,4-三氮唑-1-乙基）醋酸的合成方法

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059107A1 (en) 2001-01-23 2002-08-01 Eli Lilly And Company Substituted piperidines/piperazines as melanocortin receptor agonists
ES2246390T3 (es) 2001-01-23 2006-02-16 Eli Lilly And Company Derivados de piperazina como agonistas del receptor de melanocortina.
JP2005511475A (ja) 2001-03-02 2005-04-28 ブリストル−マイヤーズ スクイブ カンパニー メラノコルチン受容体のモジュレーターとして有用な化合物及びそれを含む製薬組成物
US20050256130A1 (en) 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
KR101255356B1 (ko) 2002-06-12 2013-04-17 케모센트릭스, 인크. 염증 및 면역 질병의 치료를 위한 ｃｃｒ１ 길항물질로서사용하기 위한 1-아릴-4-치환된 피페라진 유도체
GB0315203D0 (en) 2003-06-28 2003-08-06 Celltech R&D Ltd Chemical compounds
WO2005035534A1 (ja) 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
WO2005042516A2 (en) 2003-10-22 2005-05-12 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
CA2546754A1 (en) 2003-11-21 2005-06-09 Array Biopharma Inc. Akt protein kinase inhibitors
MY140489A (en) 2003-12-26 2009-12-31 Eisai R&D Man Co Ltd 1,2-di (cyclic) substituted benzene compounds
US20060276465A1 (en) 2003-12-26 2006-12-07 Eisai R&D Management Co., Ltd. 1,2-di(cyclic) substituted benzene compounds
WO2006047277A2 (en) 2004-10-22 2006-05-04 Janssen Pharmaceutica, N.V. Inhibitors of c-fms kinase
US7645755B2 (en) 2004-10-22 2010-01-12 Janssen Pharmaceutical N.V. Inhibitors of c-fms kinase
KR20070107075A (ko) 2005-02-16 2007-11-06 쉐링 코포레이션 Ｃｘｃｒ３ 길항제 활성을 갖는 신규의 헤테로사이클릭치환된 피리딘 또는 페닐 화합물
MX2007009949A (es) 2005-02-16 2007-09-26 Schering Corp Pirazinil-piperazin-piperidinas sustituidas con heteroarilo con actividad antagonista de cxcr3.
CA2598457A1 (en) 2005-02-16 2006-08-24 Schering Corporation Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
WO2006088920A1 (en) 2005-02-16 2006-08-24 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
CN101142209A (zh) 2005-02-16 2008-03-12 先灵公司 具有cxcr3拮抗剂活性的吡嗪基取代的哌嗪-哌啶
US7868006B2 (en) 2005-02-16 2011-01-11 Schering Corporation Heterocyclic substituted piperazines with CXCR3 antagonist activity
JP2008530212A (ja) 2005-02-16 2008-08-07 シェーリング コーポレイション Ｃｘｃｒ３アンタゴニスト活性を有するピペラジン−ピペリジン
US7777035B2 (en) 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
AU2006262122B2 (en) 2005-06-22 2013-01-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
WO2007002742A1 (en) 2005-06-28 2007-01-04 Pharmacopeia, Inc. Substituted [1,4]-diazepanes as cxcr3 antagonists and their use in the treatment of inflammatory disorders
US7754724B2 (en) 2005-06-30 2010-07-13 Dow Agrosciences Llc N-substituted piperazines
TW200738701A (en) 2005-07-26 2007-10-16 Du Pont Fungicidal carboxamides
JP2009511582A (ja) 2005-10-11 2009-03-19 シェーリング コーポレイション Ｃｘｃｒ３拮抗薬活性を有する置換複素環式化合物
NZ595182A (en) 2005-10-18 2012-12-21 Janssen Pharmaceutica Nv Pharmaceutical uses of 4-cyano-1H-imidazole-2-carboxylic acid { 2-cyclohex-1-enyl-4-[1-(2-dimethylamino-acetyl)-piperidin-4-yl]-phenyl} -amide
US20090143413A1 (en) * 2005-11-29 2009-06-04 Adams Alan D Thiazole Derivatives as CXCR3 Receptor Modulators
EP1962605A2 (en) * 2005-12-12 2008-09-03 Merck & Co., Inc. 2-arylthiazole derivatives as cxcr3 receptor modulators
WO2007076318A2 (en) 2005-12-21 2007-07-05 Smithkline Beecham Corporation Camphor-derived cxcr3 antagonists
EP1988900A2 (en) 2006-02-23 2008-11-12 Merck & Co., Inc. Pyridine, pyrimidine and pyrazine derivatives as cxcr3 receptor modulators
MX2008012161A (es) 2006-03-21 2008-10-03 Schering Corp Compuestos heterociclicos de piridina sustituida con actividad antagonista de cxcr3.
MX2008013528A (es) 2006-04-20 2008-10-29 Jannsen Pharmaceutica N V Metodo para inhibir la cinasa del c-kit.
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
FR2903405B1 (fr) 2006-07-04 2011-09-09 Pasteur Institut Composes a effet potentialisateur de l'activite de l'ethionamide et leurs applications
EP2041117B1 (en) 2006-07-14 2012-08-22 Merck Sharp & Dohme Corp. Heterocyclic substituted piperazine compounds with cxcr3 antagonist activity
WO2008013622A2 (en) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
US20120157466A1 (en) 2006-12-22 2012-06-21 Qingbei Zeng Heterocyclic compounds with cxcr3 antagonist activity
WO2008091594A2 (en) 2007-01-24 2008-07-31 E. I. Du Pont De Nemours And Company Fungicidal mixtures
PL2121660T3 (pl) 2007-01-25 2015-06-30 Du Pont Amidy grzybobójcze
WO2009020534A2 (en) 2007-08-03 2009-02-12 Schering Corporation Method of treating cxcr3 mediated diseases using heterocyclic substituted piperazines
TWI428091B (zh) 2007-10-23 2014-03-01 Du Pont 殺真菌劑混合物
EP2234971A1 (en) 2007-12-18 2010-10-06 Schering Corporation Process and intermediates for the synthesis of heterocyclic substituted piperazines with cxcr3 antagonist activity
EP2238133A2 (en) 2008-01-25 2010-10-13 E. I. du Pont de Nemours and Company Fungicidal amides
JP5529044B2 (ja) 2008-01-25 2014-06-25 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 殺菌性複素環化合物
PE20091576A1 (es) 2008-02-19 2009-11-05 Sanofi Aventis DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3
WO2009132785A1 (de) 2008-04-30 2009-11-05 Bayer Cropscience Aktiengesellschaft Thiazol-4-carbonsäureester und thioester als pflanzenschutzmittel
EP2166006A1 (en) * 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
EP2334669B1 (de) 2008-10-01 2015-12-23 Bayer Intellectual Property GmbH Heterocyclyl substituierte thiazole als pflanzenschutzmittel
KR101052065B1 (ko) 2008-10-15 2011-07-27 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법
UY32285A (es) 2008-12-02 2010-06-30 Du Pont Compuestos heterocíclicos fungicidas
BRPI0923366A2 (pt) 2008-12-11 2019-09-24 Bayer Cropscience Ag éteres e hodrazonas de oxima de tiazolila como agentes protetors de culturas.
EP2424840B1 (en) * 2009-04-27 2014-08-06 Boehringer Ingelheim International GmbH Cxcr3 receptor antagonists
US8362249B2 (en) 2009-04-27 2013-01-29 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
EP2272846A1 (de) 2009-06-23 2011-01-12 Bayer CropScience AG Thiazolylpiperidin Derivate als Fungizide
UA107938C2 (en) 2009-08-12 2015-03-10 Syngenta Participations Ag Heterocycles with microbicidal properties
NZ597562A (en) 2009-08-12 2013-10-25 Syngenta Participations Ag Microbiocidal heterocycles
WO2011051243A1 (en) 2009-10-29 2011-05-05 Bayer Cropscience Ag Active compound combinations
CN102712634B (zh) 2009-10-30 2016-04-06 拜耳知识产权有限责任公司 杂芳基哌啶和杂芳基哌嗪衍生物
CN102781937B (zh) 2009-12-21 2015-09-30 拜尔农作物科学股份公司 用作杀菌剂的双(二氟甲基)吡唑
US8952004B2 (en) 2010-01-07 2015-02-10 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
WO2011134969A1 (de) 2010-04-28 2011-11-03 Bayer Cropscience Ag Ketoheteroarylpiperidin und -piperazin derivate als fungizide
US8815775B2 (en) 2010-05-18 2014-08-26 Bayer Cropscience Ag Bis(difluoromethyl)pyrazoles as fungicides
AU2011256730B2 (en) 2010-05-20 2015-07-09 E. I. Du Pont De Nemours And Company Fungicidal oximes and hydrazones
WO2011147765A1 (de) 2010-05-27 2011-12-01 Bayer Cropscience Ag Pyridinylcarbonsäure derivate als fungizide
US20120122928A1 (en) 2010-08-11 2012-05-17 Bayer Cropscience Ag Heteroarylpiperidine and -Piperazine Derivatives as Fungicides
US8759527B2 (en) 2010-08-25 2014-06-24 Bayer Cropscience Ag Heteroarylpiperidine and -piperazine derivatives as fungicides
MX352731B (es) 2010-10-27 2017-12-06 Bayer Ip Gmbh Derivados de heteroarilpiperidina y -piperazina como fungicidas.
EP2643312B1 (en) 2010-11-25 2014-09-10 Syngenta Participations AG Microbicidal heterocycles
CN103384470A (zh) 2010-12-17 2013-11-06 纳幕尔杜邦公司 杀真菌偶氮环酰胺
CN104987330B (zh) 2011-02-01 2019-04-05 拜耳知识产权有限责任公司 作为杀真菌剂的杂芳基哌啶和杂芳基哌嗪衍生物
WO2012107477A1 (en) 2011-02-10 2012-08-16 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2012107475A1 (en) 2011-02-10 2012-08-16 Syngenta Participations Ag Microbiocidal pyrazole derivatives
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
WO2013037768A1 (de) 2011-09-15 2013-03-21 Bayer Intellectual Property Gmbh Piperidinpyrazole als fungizide
CN103889982A (zh) 2011-10-18 2014-06-25 先正达参股股份有限公司 杀微生物的吡唑衍生物
WO2013056911A1 (en) 2011-10-18 2013-04-25 Syngenta Participations Ag Microbiocidal pyrazole derivatives
US8642774B2 (en) 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
NZ627560A (en) 2012-01-25 2016-08-26 Novartis Ag Heterocyclic piperazine compounds and methods for their use
ES2632237T3 (es) * 2012-02-02 2017-09-12 Idorsia Pharmaceuticals Ltd Compuestos de 4-(benzoimidazol-2-il)-tiazol y derivados aza relacionados
EP2820015A1 (en) 2012-03-02 2015-01-07 Syngenta Participations AG Microbiocidal pyrazole derivatives
IN2012DE00620A (es) 2012-03-02 2015-08-21 Syngenta Participations Ag
TWI570120B (zh) 2012-06-04 2017-02-11 艾克泰聯製藥有限公司 苯并咪唑脯胺酸衍生物
US10035790B2 (en) 2012-10-19 2018-07-31 Exelixis, Inc. RORγ modulators
WO2014075874A1 (en) 2012-11-13 2014-05-22 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2014075873A1 (en) 2012-11-13 2014-05-22 Syngenta Participations Ag Microbiocidal pyrazole derivatives
KR20150093240A (ko) 2012-12-11 2015-08-17 다케다 야쿠힌 고교 가부시키가이샤 헤테로시클릭 화합물
ES2672736T3 (es) 2013-06-24 2018-06-15 Bayer Cropscience Aktiengesellschaft Derivados de ácido piperidincarboxílico como fungicidas
MX363432B (es) 2013-07-22 2019-03-22 Idorsia Pharmaceuticals Ltd Derivados 1-(piperazin-1-il)-2-([1,2,4]triazol-1-il)-etanona.
WO2015026683A1 (en) 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
AR099789A1 (es) 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
AR102256A1 (es) 2014-10-15 2017-02-15 Actelion Pharmaceuticals Ltd Derivados biaromáticos básicos antibacterianos con sustitución de aminoalcoxi
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
NZ734542A (en) 2015-01-15 2023-02-24 Idorsia Pharmaceuticals Ltd Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators

Also Published As

Publication number Publication date
CA2972954A1 (en) 2016-07-21
CN107207491B (zh) 2020-08-25
US10047080B2 (en) 2018-08-14
TWI698434B (zh) 2020-07-11
AU2016207990B2 (en) 2020-01-30
CN107207491A (zh) 2017-09-26
RU2017128880A (ru) 2019-02-15
ES2712727T3 (es) 2019-05-14
TR201901977T4 (tr) 2019-03-21
RU2017128880A3 (es) 2019-06-06
BR112017015116A2 (pt) 2018-04-10
WO2016113346A1 (en) 2016-07-21
TW201632518A (zh) 2016-09-16
EP3256469B1 (en) 2018-11-28
US20180009800A1 (en) 2018-01-11
JP2018502162A (ja) 2018-01-25
JP6595003B2 (ja) 2019-10-23
KR102568469B1 (ko) 2023-08-18
RU2706232C2 (ru) 2019-11-15
AR103399A1 (es) 2017-05-10
KR20170102355A (ko) 2017-09-08
CA2972954C (en) 2023-08-29
EP3256469A1 (en) 2017-12-20
PL3256469T3 (pl) 2019-05-31
AU2016207990A1 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
PH12018500591B1 (en) Heterocyclic compounds and uses thereof
TW201613911A (en) Heterocyclic compounds and uses thereof
PH12015501996A1 (en) Heterocyclic compounds and uses thereof
PH12017502266A1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2017000524A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12014502540A1 (en) Benzimidazole-proline derivatives
PH12017501280B1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
MX2016012451A (es) Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina.
TW201613864A (en) Novel compounds
MX2017014035A (es) Formas solidas novedosas.
MY181641A (en) Amino pyran ring derivative and composition and use thereof
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.
SA518390920B1 (ar) مركبات فينوكسي أسيتاميد معالجة بإضافة حلقة
NZ721780A (en) Heterocyclic modulators of lipid synthesis for use against cancer and viral infections
PH12018500377A1 (en) Novel annelated benzamides
PH12018501709A1 (en) Naphthridinedione derivatives
MX2018001517A (es) Derivados sustituidos de guanidina.
PH12015502632A1 (en) Cxcr7 receptor modulators
EA201600123A1 (ru) Производные 1-(пиперазин-1-ил)-2-([1,2,4]триазол-1-ил)этанона
HK1219723A1 (zh) 作为前动力蛋白受体调节剂的派啶和氮杂䓬衍生物

Legal Events

Date Code Title Description
FG Grant or registration